Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 March 2008, Vol. 111, No. 6, pp. 3257-3265.
Prepublished online as a Blood First Edition Paper on December 12, 2007; DOI 10.1182/blood-2007-06-096081.


This Article
Right arrow Full Text (PDF)
Right arrow Supplemental Figures
Right arrow All Versions of this Article:
blood-2007-06-096081v1
111/6/3257    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jasperson, L. K
Right arrow Articles by Blazar, B. R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jasperson, L. K
Right arrow Articles by Blazar, B. R
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted June 15, 2007
Accepted November 17, 2007

Indoleamine 2,3-dioxygenase is a critical regulator of acute GVHD lethality

Lisa K Jasperson, Christoph Bucher, Angela Panoskaltsis-Mortari, Patricia A Taylor, Andrew L Mellor, David H Munn, and Bruce R Blazar*

Cancer Center and Department of Pediatrics, Division of BMT, University of Minnesota, Minneapolis, MN, United States
Immunotherapy Center, Medical College of Georgia, Augusta, GA, United States

* Corresponding author; email: blaza001{at}umn.edu.

Graft versus host disease (GVHD) is initiated following activation of donor T cells by host antigen presenting cells (APCs). The immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) is expressed by APCs and parenchymal cells and is further inducible by inflammation. We investigated whether lethal conditioning and GVHD induce IDO and if IDO prevents tissue injury by suppressing immune responses at the induction site. We determined IDO is a critical regulator of GVHD, most strikingly in the colon, where epithelial cells dramatically upregulated IDO expression during GVHD. IDO-/- mice died more quickly from GVHD, displaying increased colonic inflammation and T cell infiltration. GVHD protection was not mediated by control of T cell proliferation, apoptosis, or effector mechanisms in lymphoid organs, nor did it require donor T regulatory cells (Tregs). Instead, T cells in IDO-/- colons underwent increased proliferation and decreased apoptosis compared to their wild-type counterparts. This evidence suggests IDO can act at the site of expression to decrease T cell proliferation and survival, diminishing colonic inflammation and reducing disease severity. These studies are the first to identify a function for IDO in GVHD lethality and indicate modulation of the IDO pathway may be an effective strategy for treatment of this disease.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

More ADO about IDO: GVHD
Antonio Curti, Sara Trabanelli, and Roberto M. Lemoli
Blood 2008 111: 2950. [Full Text] [PDF]





 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020